Cohen & Steers, Inc. (CNS) — Fair Value Analysis

Base-case fair value (P50): $57.92 · Current price: $78.57 · Verdict: Overvalued

The Verdict on CNS

Based on our proprietary Monte Carlo simulations, COHEN & STEERS INC (CNS) is currently Overvalued. Our analysis, which models thousands of potential future scenarios, indicates a median fair value (P50) of $57.92. This suggests a significant -26.3% downside compared to the current trading price of $78.57. The quantitative assessment positions CNS firmly in the overvalued category, challenging its present market valuation. While CNS remains unrated for operational and financial health against its sector, the clear outcome from our probabilistic models provides a robust signal to the market.

How CNS stacks up against peers

The "unrated" quality tier for CNS means its operational and financial health isn't explicitly benchmarked against sector peers within our system. However, the Monte Carlo simulation offers a robust, data-driven perspective on its standalone valuation. Our models project a median fair value of $57.92, standing in stark contrast to the current market price of $78.57. This substantial -26.3% discrepancy signals that, irrespective of traditional peer-group comparisons or an assigned sector rating, the underlying simulated value metrics point to significant overvaluation. For investors, this pronounced gap between $78.57 and $57.92 highlights a fundamental disconnect identified by our forward-looking probabilistic models.

What this means for investors

The Overvalued verdict for CNS, driven by the substantial -26.3% gap between its current price of $78.57 and the median fair value of $57.92, warrants immediate investor attention. For those considering an entry point or re-evaluating existing positions, the Monte Carlo simulation suggests that CNS is trading significantly above its intrinsic value based on thousands of potential future scenarios. This analysis, especially given CNS's unrated quality tier, emphasizes the quantitative signal from our fair value models in the absence of a traditional quality benchmark. Investors should carefully consider the implications of CNS's current valuation at $78.57 relative to its statistically derived fair value. Explore FairCurve to access the full distribution of bear and bull case scenarios and track CNS's fair value as new fundamentals are released.